{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"1"}],"units":"Participants"}],"description":"TEAE is defined as an adverse event reported for the first time or worsening of a pre-existing event after the first dose of study treatment.","groups":[{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG000","title":"Part 1 / Treatment Group A: 15 MG QD INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG001","title":"Part 1 / Treatment Group A: 22.5 MG QD INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG002","title":"Part 1 / Treatment Group A: 15 MG BID INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG003","title":"Part 1 / Treatment Group A: 30 MG QD INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG004","title":"Part 1 / Treatment Group A: 22.5 MG BID INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. 5/2=5 days on/2 days off.\n\nTreatment Group A included any advanced solid tumor or lymphoma.","id":"OG005","title":"Part 1 / Treatment Group A: 22.5 MG BID 5/2 INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. 4/3=4 days on/3 days off. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG006","title":"Part 1 / Treatment Group A: 22.5 MG BID 4/3 INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. 7/7=7 days on/7 days off. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG007","title":"Part 1 / Treatment Group A: 22.5 MG BID 7/7 INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG008","title":"Part 1 / Treatment Group A: 20 MG BID INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. 5/2=5 days on/2 days off. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG009","title":"Part 1 / Treatment Group A: 25 MG BID 5/2 INCB054329"},{"description":"Part 1 / treatment group A (TGA): Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the TGA. 7/7=7 days on/7 days off. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG010","title":"Part 1 / Treatment Group A: 25 MG BID 7/7 INCB054329"},{"description":"Part 1 / treatment group B (TGB): Initial cohort dose of INCB054329 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms, or myelofibrosis.","id":"OG011","title":"Part 1 / Treatment Group B: 20 MG BID INCB054329"},{"description":"Part 2 / treatment group A (TGA): dose titration was to determine the feasibility of intraparticipant dose titration using Protocol-defined criteria. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG012","title":"Part 2 / Treatment Group A: 20 MG BID INCB054329"},{"description":"Part 2 / treatment group C (TGC): dose titration was to determine the feasibility of intraparticipant dose titration using Protocol-defined criteria. Treatment Group C included multiple myeloma.","id":"OG013","title":"Part 2 / Treatment Group C: 20 mg BID INCB054329"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety population included all enrolled participants who received at least 1 dose of INCB054329.","reportingStatus":"POSTED","timeFrame":"up to 30 days","title":"Number of Participants With a Treatment-emergent Adverse Event (TEAE)","type":"PRIMARY","unitOfMeasure":"Participants"}